{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:47:13Z","timestamp":1761238033161},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T00:00:00Z","timestamp":1381536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11906-013-0394-8","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T17:48:32Z","timestamp":1381513712000},"page":"614-622","source":"Crossref","is-referenced-by-count":16,"title":["An Update on Medical Therapy for Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"15","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot S.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,12]]},"reference":[{"issue":"5","key":"394_CR1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"394_CR2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1378\/chest.10-2327","volume":"140","author":"R Zhang","year":"2011","unstructured":"\u2022\u2022 Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest. 2011;140(2):301\u20139. The study reported that although the medical insurance system is insufficient in China, there is still a significant and rapid improvement in survival of PAH patients when the targeted therapies are employed, compared with that from 2007 registry.","journal-title":"Chest"},{"issue":"2","key":"394_CR3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","volume":"142","author":"RL Benza","year":"2012","unstructured":"\u2022\u2022 Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448\u201356. This registry includes more than 2,600 patients from 55 US centers, and is currently the largest survival registry worldwide. The study authoritatively suggests considerable improvements in survival in the past two decades since targeted medications for PAH were developed.","journal-title":"Chest"},{"issue":"12","key":"394_CR4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477\u201382.","journal-title":"Circulation"},{"issue":"4","key":"394_CR5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"394_CR6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","volume":"99","author":"EB Rosenzweig","year":"1999","unstructured":"Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858\u201365.","journal-title":"Circulation"},{"issue":"10","key":"394_CR7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1164\/rccm.200204-330OC","volume":"167","author":"H Nunes","year":"2003","unstructured":"Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167(10):1433\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"394_CR8","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2146\/ajhp110687","volume":"69","author":"A Fuentes","year":"2012","unstructured":"Fuentes A, Coralic A, Dawson KL. A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. Am J Health Syst Pharm. 2012;69(16):1389\u201393.","journal-title":"Am J Health Syst Pharm"},{"key":"394_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/DDDT.S31628","volume":"6","author":"O Lambert","year":"2012","unstructured":"Lambert O, Bandilla D. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des Devel Ther. 2012;6:235\u201344.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"394_CR10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"394_CR11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","volume":"104","author":"H Olschewski","year":"2010","unstructured":"Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104(5):731\u201340.","journal-title":"Respir Med"},{"issue":"10","key":"394_CR12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.cardfail.2011.05.012","volume":"17","author":"AM Martischnig","year":"2011","unstructured":"Martischnig AM, Tichy A, Nikfardjam M, et al. Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure. J Card Fail. 2011;17(10):813\u20138.","journal-title":"J Card Fail"},{"issue":"6","key":"394_CR13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1183\/09031936.00169608","volume":"33","author":"ZC Jing","year":"2009","unstructured":"Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;33(6):1354\u201360.","journal-title":"Eur Respir J"},{"key":"394_CR14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2466-11-56","volume":"11","author":"L Knudsen","year":"2011","unstructured":"Knudsen L, Schurawlew A, Nickel N, et al. Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC Pulm Med. 2011;11:56.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"394_CR15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1183\/09031936.00130408","volume":"34","author":"MM Hoeper","year":"2009","unstructured":"Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J. 2009;34(1):132\u20137.","journal-title":"Eur Respir J"},{"issue":"1","key":"394_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erc.12.160","volume":"11","author":"F Torres","year":"2013","unstructured":"Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11(1):13\u201325.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"6","key":"394_CR17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"394_CR18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","volume":"55","author":"VV McLaughlin","year":"2010","unstructured":"McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"394_CR19","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","volume":"28","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195\u2013203.","journal-title":"Eur Respir J"},{"issue":"6","key":"394_CR20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","volume":"129","author":"I Lang","year":"2006","unstructured":"Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636\u201343.","journal-title":"Chest"},{"issue":"5","key":"394_CR21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.amjcard.2006.09.119","volume":"99","author":"DD Ivy","year":"2007","unstructured":"Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol. 2007;99(5):696\u20138.","journal-title":"Am J Cardiol"},{"issue":"3","key":"394_CR22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2011\/104834","volume":"18","author":"K Park","year":"2011","unstructured":"Park K, Ostrow D, Levy RD, et al. Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic review. Can Respir J. 2011;18(3):157\u201362.","journal-title":"Can Respir J"},{"issue":"3","key":"394_CR23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.rmed.2012.10.023","volume":"107","author":"OA Minai","year":"2013","unstructured":"Minai OA, Parambil J, Dweik RA, et al. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Respir Med. 2013;107(3):458\u201365.","journal-title":"Respir Med"},{"issue":"4","key":"394_CR24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.healun.2011.12.011","volume":"31","author":"R Badagliacca","year":"2012","unstructured":"Badagliacca R, Pezzuto B, Poscia R, et al. Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. J Heart Lung Transplant. 2012;31(4):364\u201372.","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"394_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12325-011-0005-5","volume":"28","author":"JL Vachiery","year":"2011","unstructured":"Vachiery JL. Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Adv Ther. 2011;28(4):251\u201369.","journal-title":"Adv Ther"},{"key":"394_CR26","doi-asserted-by":"crossref","first-page":"903A","DOI":"10.1378\/chest.1118152","volume":"140","author":"HW Farber","year":"2011","unstructured":"Farber HW, Miller DP, Beery FS, et al. Use of parenteral prostanoids at time of death in patients with pulmonary arterial hypertension in REVEAL. Chest. 2011;140:903A.","journal-title":"Chest"},{"issue":"12","key":"394_CR27","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","volume":"41","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"394_CR28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","volume":"39","author":"N Galie","year":"2002","unstructured":"Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496\u2013502.","journal-title":"J Am Coll Cardiol"},{"issue":"126","key":"394_CR29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09059180.00004812","volume":"21","author":"O Sitbon","year":"2012","unstructured":"Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012;21(126):321\u20137.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"394_CR30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383\u201390.","journal-title":"Chest"},{"key":"394_CR31","doi-asserted-by":"crossref","unstructured":"Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): a randomized controlled trial. Chest. 2013. [Epub ahead of print].","DOI":"10.1378\/chest.12-2875"},{"issue":"5","key":"394_CR32","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","volume":"127","author":"ZC Jing","year":"2013","unstructured":"Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624\u201333.","journal-title":"Circulation"},{"issue":"4","key":"394_CR33","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","volume":"40","author":"G Simonneau","year":"2012","unstructured":"\u2022 Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874\u201380. This phase II proof-of-concept study evaluated the safety and efficacy of selexipag, the encouraging results facilitate the ongoing multicenter, randomised GRIPHON study, in which time to first morbidity or mortality event is employed as the primary endpoint.","journal-title":"Eur Respir J"},{"issue":"2","key":"394_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/2045-8932.97589","volume":"2","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, Channick R, Ivy D, et al. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ. 2012;2(2):139\u201347.","journal-title":"Pulm Circ"},{"issue":"20","key":"394_CR35","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"394_CR36","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417\u201322.","journal-title":"J Rheumatol"},{"issue":"3","key":"394_CR37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2006.10.018","volume":"120","author":"EM Chau","year":"2007","unstructured":"Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120(3):301\u20135.","journal-title":"Int J Cardiol"},{"issue":"5","key":"394_CR38","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","volume":"140","author":"LJ Rubin","year":"2011","unstructured":"Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140(5):1274\u201383.","journal-title":"Chest"},{"issue":"10","key":"394_CR39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/hr.2009.113","volume":"32","author":"XQ Xu","year":"2009","unstructured":"Xu XQ, Jing ZC, Zhang JH, et al. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertens Res. 2009;32(10):911\u20135.","journal-title":"Hypertens Res"},{"issue":"3","key":"394_CR40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0091270011398241","volume":"52","author":"CM Xiong","year":"2012","unstructured":"Xiong CM, Lu XL, Shan GL, et al. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. J Clin Pharmacol. 2012;52(3):425\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"394_CR41","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1136\/heartjnl-2011-300344","volume":"97","author":"ZN Zhang","year":"2011","unstructured":"\u2022 Zhang ZN, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97(22):1876\u201381. This study indicated that oral sildenafil taken over 1 year was well tolerated and seemed to improved exercise capacity, hemodynamic measurements as well as systemic arterial oxygen in patients with Eisenmenger syndrome, this is important because there is a large population of patients with Eisenmenger syndrome in China, sildenafil provieds a valuable therapeutic option.","journal-title":"Heart"},{"issue":"22","key":"394_CR42","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894\u2013903.","journal-title":"Circulation"},{"issue":"6","key":"394_CR43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","volume":"30","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632\u201343.","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"394_CR44","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","volume":"60","author":"RJ Oudiz","year":"2012","unstructured":"Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"394_CR45","doi-asserted-by":"crossref","unstructured":"Shapiro SM, Traiger G, Hill W, et al. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther. 2013. [Epub ahead of print].","DOI":"10.1111\/1755-5922.12038"},{"issue":"12","key":"394_CR46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","volume":"183","author":"ZC Jing","year":"2011","unstructured":"\u2022 Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723\u20139. The study is the first randomized, controlled study to assess the effect of another PDE-5 inibitor vardenafil on PAH. Vardenafil was shown to be effective and well tolerated in patients with PAH.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"394_CR47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cvr\/cvt109","volume":"99","author":"YF Fan","year":"2013","unstructured":"Fan YF, Zhang R, Jiang X, et al. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res. 2013;99(3):395\u2013403.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"394_CR48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"\u2022\u2022 Ghofrani HA, D\u2019Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329. This study reveals that Riociguat, a new candidate treating pulmonary hypertension, can significantly improve exercise capacity, PVR and NT-proBNP level of patients with CTEPH. Based on the results, riociguat would probably the first drug appoved for inoperable CTEPH.","journal-title":"N Engl J Med"},{"issue":"4","key":"394_CR49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"\u2022\u2022 Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340. Similar to the above CHEST study, riociguat in this study significantly improved exercise capacity, PVR, NT-proBNP level and time to clinical worsening. These two studies lead to an FDA submission for approval of riociguat for CTEPH and PAH.","journal-title":"N Engl J Med"},{"issue":"12","key":"394_CR50","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903.","journal-title":"N Engl J Med"},{"issue":"10","key":"394_CR51","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/ard.2005.048967","volume":"65","author":"CP Denton","year":"2006","unstructured":"Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"394_CR52","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","volume":"170","author":"O Sitbon","year":"2004","unstructured":"Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"394_CR53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00005-5","volume":"73","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73(4):372\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"394_CR54","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1183\/09031936.05.00080804","volume":"25","author":"MM Hoeper","year":"2005","unstructured":"Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25(3):502\u20138.","journal-title":"Eur Respir J"},{"issue":"9630","key":"394_CR55","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","volume":"371","author":"N Galie","year":"2008","unstructured":"Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093\u2013100.","journal-title":"Lancet"},{"issue":"1","key":"394_CR56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1183\/09031936.00053510","volume":"38","author":"AA Hislop","year":"2011","unstructured":"Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J. 2011;38(1):70\u20137.","journal-title":"Eur Respir J"},{"issue":"1","key":"394_CR57","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2011.06.064","volume":"164","author":"JC Vis","year":"2013","unstructured":"Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164(1):64\u20139.","journal-title":"Int J Cardiol"},{"issue":"8","key":"394_CR58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.recesp.2011.04.016","volume":"64","author":"P Avellana","year":"2011","unstructured":"Avellana P, Segovia J, Sufrate E, et al. Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension. Rev Esp Cardiol. 2011;64(8):667\u201373.","journal-title":"Rev Esp Cardiol"},{"issue":"2","key":"394_CR59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","volume":"30","author":"M Humbert","year":"2007","unstructured":"Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30(2):338\u201344.","journal-title":"Eur Respir J"},{"issue":"23","key":"394_CR60","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Galie","year":"2008","unstructured":"Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139.","journal-title":"Circulation"},{"issue":"21","key":"394_CR61","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(21):1971\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"394_CR62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacc.2012.03.025","volume":"60","author":"O Ben-Yehuda","year":"2012","unstructured":"\u2022 Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012;60(1):80\u20131. The post-marketing monitoring with more than 10,000 patients exposed to ambrisentan during the 3.5-year period showed the rate of clinically important elevations in liver enzymes was similar to that in placebo-treated patients, leading the FDA to cancel the requirment of monthly monitoring of liver function when patients receiving ambrisentan.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"394_CR63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","volume":"135","author":"MD McGoon","year":"2009","unstructured":"McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122\u20139.","journal-title":"Chest"},{"issue":"3","key":"394_CR64","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736\u201345.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"394_CR65","first-page":"1066","volume":"11","author":"SG Raja","year":"2010","unstructured":"Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2010;11(9):1066\u201373.","journal-title":"Curr Opin Investig Drugs"},{"key":"394_CR66","first-page":"A3631","volume":"185","author":"G Raghu","year":"2012","unstructured":"Raghu G, Million-Rousseau R, Morganti A, et al. Efficacy and safety of macitentan in idiopathic pulmonary fibrosis: results of a prospective, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2012;185:A3631.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"394_CR67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","volume":"8","author":"D Montani","year":"2013","unstructured":"Montani D, Gunther S, Dorfmuller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013;8(1):97.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"394_CR68","first-page":"386","volume":"32","author":"N Galie","year":"2011","unstructured":"Galie N, Hoeper MM, Simon J, et al. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Heart J. 2011;32(4):386\u20137.","journal-title":"Eur Heart J"},{"issue":"1","key":"394_CR69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca.09.54","volume":"6","author":"MK Chhina","year":"2010","unstructured":"Chhina MK, Nargues W, Grant GM, et al. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol. 2010;6(1):19\u201335.","journal-title":"Future Cardiol"},{"issue":"10","key":"394_CR70","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"\u2022 Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study. Circulation. 2013;127(10):1128\u201338. Imatinib as a novel but potential candidate agent for PAH was evaluated in this randomized study, results showed benificial effects of the drug as an add-on therapy in patients with advanced PAH, however, serious adverse events and discontinuations may limit the use of the drug.","journal-title":"Circulation"},{"issue":"22","key":"394_CR71","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1161\/CIRCULATIONAHA.108.767558","volume":"117","author":"Y Dempsie","year":"2008","unstructured":"Dempsie Y, Morecroft I, Welsh DJ, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation. 2008;117(22):2928\u201337.","journal-title":"Circulation"},{"issue":"5","key":"394_CR72","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","volume":"37","author":"R Dumitrascu","year":"2011","unstructured":"Dumitrascu R, Kulcke C, Konigshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011;37(5):1104\u201318.","journal-title":"Eur Respir J"},{"issue":"3","key":"394_CR73","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1378\/chest.08-2823","volume":"136","author":"SJ Shah","year":"2009","unstructured":"Shah SJ, Gomberg-Maitland M, Thenappan T, et al. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest. 2009;136(3):694\u2013700.","journal-title":"Chest"},{"issue":"5","key":"394_CR74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pupt.2006.01.001","volume":"19","author":"SM Kawut","year":"2006","unstructured":"Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2006;19(5):370\u20134.","journal-title":"Pulm Pharmacol Ther"},{"key":"394_CR75","first-page":"A2496","volume":"185","author":"HA Ghofrani","year":"2012","unstructured":"Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med. 2012;185:A2496.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"394_CR76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1378\/chest.11-0426","volume":"141","author":"IA Dhalla","year":"2012","unstructured":"Dhalla IA, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case\u2013control study. Chest. 2012;141(2):348\u201353.","journal-title":"Chest"},{"issue":"10","key":"394_CR77","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","volume":"115","author":"SI Said","year":"2007","unstructured":"Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 2007;115(10):1260\u20138.","journal-title":"Circulation"},{"issue":"1","key":"394_CR78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.00105807","volume":"31","author":"SA Hamidi","year":"2008","unstructured":"Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J. 2008;31(1):135\u20139.","journal-title":"Eur Respir J"},{"issue":"5","key":"394_CR79","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","volume":"32","author":"HH Leuchte","year":"2008","unstructured":"Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008;32(5):1289\u201394.","journal-title":"Eur Respir J"},{"issue":"4","key":"394_CR80","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1183\/09031936.00130209","volume":"36","author":"KT Mouchaers","year":"2010","unstructured":"Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36(4):800\u20137.","journal-title":"Eur Respir J"},{"issue":"3","key":"394_CR81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/hrt.2003.029470","volume":"91","author":"Y Fukumoto","year":"2005","unstructured":"Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91(3):391\u20132.","journal-title":"Heart"},{"issue":"3","key":"394_CR82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00246-008-9315-z","volume":"30","author":"F Li","year":"2009","unstructured":"Li F, Xia W, Yuan S, et al. Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol. 2009;30(3):363\u20136.","journal-title":"Pediatr Cardiol"},{"key":"394_CR83","doi-asserted-by":"crossref","unstructured":"Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013. [Epub ahead of print].","DOI":"10.1253\/circj.CJ-13-0443"},{"issue":"4","key":"394_CR84","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/HCO.0b013e32834659bf","volume":"26","author":"N Katsiki","year":"2011","unstructured":"Katsiki N, Wierzbicki AS, Mikhailidis DP. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol. 2011;26(4):322\u20136.","journal-title":"Curr Opin Cardiol"},{"issue":"25","key":"394_CR85","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1161\/CIRCULATIONAHA.110.015693","volume":"123","author":"SM Kawut","year":"2011","unstructured":"Kawut SM, Bagiella E, Lederer DJ, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011;123(25):2985\u201393.","journal-title":"Circulation"},{"issue":"1","key":"394_CR86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1183\/09031936.00149011","volume":"40","author":"WJ Zeng","year":"2012","unstructured":"Zeng WJ, Xiong CM, Zhao L, et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J. 2012;40(1):67\u201374.","journal-title":"Eur Respir J"},{"issue":"1","key":"394_CR87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccm.2006.11.011","volume":"28","author":"DS O\u2019Callaghan","year":"2007","unstructured":"O\u2019Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):169\u201385. ix.","journal-title":"Clin Chest Med"},{"issue":"5","key":"394_CR88","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","volume":"27","author":"S Provencher","year":"2006","unstructured":"Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589\u201395.","journal-title":"Eur Heart J"},{"issue":"5","key":"394_CR89","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","volume":"26","author":"MM Hoeper","year":"2005","unstructured":"Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26(5):858\u201363.","journal-title":"Eur Respir J"},{"issue":"3","key":"394_CR90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","volume":"24","author":"M Humbert","year":"2004","unstructured":"Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353\u20139.","journal-title":"Eur Respir J"},{"issue":"11","key":"394_CR91","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","volume":"174","author":"VV McLaughlin","year":"2006","unstructured":"McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257\u201363.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"394_CR92","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","volume":"28","author":"MM Hoeper","year":"2006","unstructured":"Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691\u20134.","journal-title":"Eur Respir J"},{"issue":"8","key":"394_CR93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","volume":"149","author":"G Simonneau","year":"2008","unstructured":"Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521\u201330.","journal-title":"Ann Intern Med"},{"issue":"8","key":"394_CR94","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.amjcard.2011.06.021","volume":"108","author":"BD Fox","year":"2011","unstructured":"Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108(8):1177\u201382.","journal-title":"Am J Cardiol"},{"issue":"4","key":"394_CR95","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/FJC.0b013e318262a793","volume":"60","author":"B Zhu","year":"2012","unstructured":"Zhu B, Wang L, Sun L, et al. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. J Cardiovasc Pharmacol. 2012;60(4):342\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"394_CR96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","volume":"120","author":"Y Bai","year":"2011","unstructured":"Bai Y, Sun L, Hu S, et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology. 2011;120(3):157\u201365.","journal-title":"Cardiology"},{"issue":"Suppl 1","key":"394_CR97","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.mcp.0000370205.22885.98","volume":"16","author":"A Peacock","year":"2010","unstructured":"Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med. 2010;16 Suppl 1:S1\u20139.","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"394_CR98","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/2045-8932.109920","volume":"3","author":"PM Hassoun","year":"2013","unstructured":"Hassoun PM, Nikkho S, Rosenzweig EB, et al. Updating clinical endpoint definitions. Pulm Circ. 2013;3(1):206\u201316.","journal-title":"Pulm Circ"},{"issue":"6","key":"394_CR99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1513\/pats.201105-035MW","volume":"8","author":"DJ Stewart","year":"2011","unstructured":"Stewart DJ, Mei SH. Cell-based therapies for lung vascular diseases: lessons for the future. Proc Am Thorac Soc. 2011;8(6):535\u201340.","journal-title":"Proc Am Thorac Soc"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0394-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-013-0394-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-013-0394-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T17:15:54Z","timestamp":1564506954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-013-0394-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,12]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s11906-013-0394-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,12]]}}}